What is the drug thought to do in the body?

Triumeq is a drug that is used to treat patients with the human immunodeficiency virus (HIV) and is shown to be safe. It is thought that ancient viruses (retroviruses) have left their genetic material in our DNA during the human evolution. In some people, this old genetic material may become activated and is believed to be a cause of MND. Triumeq is a anti-retroviral which aims to reduce the amount of these viruses (viral load) within the body.

Phase 3 (LIGHTHOUSE II)

Current status: Collecting data

Primary objective: To investigate the impact of triumeq on survival at 24 months 

Lighthouse II is a phase 3 randomized, double-blind, placebo-controlled study. This means that participants will be randomly allocated to receive a treatment with either triumeq or a placebo (dummy drug). The trial aims to enroll 390 participants, who will take triumeq for a maximum of 24 months. Find out more on the MND Clinical Studies Group website or on clinicaltrials.gov.

How can I take part in the trial?

Recruiting Sites

Recruitment for this trial is now closed.

 

Trial Information

Phase: Phase 3

Placebo Controlled: Yes - this means that people joining the trial could be randomly assigned to receive the placebo (dummy drug). 

Open-Label Extension: No - this means that participants will only receive either the treatment or the placebo throughout the trial. 

Previous Clinical Trials

Phase 2 (LIGHTHOUSE)

The Phase 2 trial (called Lighthouse), showed that triumeq could suppress the genetic reactivation and may slow disease progression in people living with MND. Triumeq was shown to be safe and well tolerated in people living with MND. However, this was a small open label trial, meaning it was not tested against a placebo and more evidence is needed to see if triumeq is beneficial for people with MND. You can read more about this trial here or in a publication here.

Latest News

2024

September 2024 - The trial closed for recruitment

2022

Sept 2022 - The trial began recruiting in the UK.

Last updated: 03/09/2024